Information Library

Results for: Clinical and marketing materials - Clinical Services - Lifecycle Safety

In the complex environment of the New Health, Quintiles is committed to helping you succeed. At every stage of your product’s lifecycle, we are dedicated to delivering real results, being proactive in navigating issues and thinking of new solutions.  Search our library today.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Pioneering Pulmonary Research

    Case Study — May 8, 2012
    Discover how Quintiles helped one sponsor modify their recruitment sites to generate the desired number of qualified patients to meet timelines in this Phase II double-blind, placebo-controlled efficacy and safety study for COPD patients with emphysema.

  • Clinical – Smarter Trials, Accelerated Outcomes

    Brochure — February 16, 2011
    Quintiles will work with you to plan and execute the smartest clinical trials and post-marketing studies, informed by a holistic view of strategic, operational, regulatory and marketplace issues.

  • Oversight Group Management Services - Aligned Action

    Brochure — February 2, 2011
    From data monitoring committees and endpoint adjudication to core laboratory oversight, Quintiles provides a one-stop solution for managing oversight groups.

  • Superior Teamwork - Renal Transplants

    Case Study — February 2, 2011
    901 patients were randomized according to the protocol timelines. The database lock was achieved 11 days before the original target date.

  • Bypassing Barriers - Refractory Partial Epilepsy

    Case Study — February 2, 2011
    Despite a difficult and limited patient population, Quintiles randomized 388 patients (13 over target) 10 weeks ahead of schedule.

  • The New Health Clinical Brochure

    Brochure — August 31, 2010
    Japanese version available for download.

  • Risk Mitigation Programs

    Brochure — April 16, 2009
    Risk mitigation measures can help keep valuable drugs on the market, even when their safety profile includes adverse events that might negatively affect the benefit risk balance.

  • Risk Assessment & Strategy

    Brochure — April 16, 2009
    Quintiles benefit risk analysis can help you anticipate potential regulatory concerns and highlight the benefit side of your drug’s benefit risk profile.

  • Phase IIIb/IV Studies

    Brochure — April 16, 2009
    New, more efficient delivery models help meet the increasing demands of Phase IIIB/IV Studies.

  • Late Phase and Safety Services

    Brochure — April 10, 2009
    Recent and pending regulatory changes have created an atmosphere of watchful waiting throughout the industry. While it may seem premature to initiate post-marketing studies to collect more “intelligent” safety data, Quintiles Late Phase & Safety Services anticipates that the need for expanded studies will soon spread.

Page 1 of 1 (10 results)

Subscribe to Email Based on Your Interests

Set preferences